| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
National Medical Center, Institute of Hematology and Immunology, Membrane Research Group, and Institute of Enzymology, Hungarian Academy of Sciences, Budapest, Hungary
In this review we give an overview of the physiological functions of a group of ATP binding cassette (ABC) transporter proteins, which were discovered, and still referred to, as multidrug resistance (MDR) transporters. Although they indeed play an important role in cancer drug resistance, their major physiological function is to provide general protection against hydrophobic xenobiotics. With a highly conserved structure, membrane topology, and mechanism of action, these essential transporters are preserved throughout all living systems, from bacteria to human. We describe the general structural and mechanistic features of the human MDR-ABC transporters and introduce some of the basic methods that can be applied for the analysis of their expression, function, regulation, and modulation. We treat in detail the biochemistry, cell biology, and physiology of the ABCB1 (MDR1/P-glycoprotein) and the ABCG2 (MXR/BCRP) proteins and describe emerging information related to additional ABCB- and ABCG-type transporters with a potential role in drug and xenobiotic resistance. Throughout this review we demonstrate and emphasize the general network characteristics of the MDR-ABC transporters, functioning at the cellular and physiological tissue barriers. In addition, we suggest that multidrug transporters are essential parts of an innate defense system, the "chemoimmunity" network, which has a number of features reminiscent of classical immunology.
This article has been cited by other articles:
|
|
 |
|
  N. Yoshida, T. Takada, Y. Yamamura, I. Adachi, H. Suzuki, and J. Kawakami Inhibitory Effects of Terpenoids on Multidrug Resistance-Associated Protein 2- and Breast Cancer Resistance Protein-Mediated Transport Drug Metab. Dispos., July 1, 2008; 36(7): 1206 - 1211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Luckenbach and D. Epel ABCB- and ABCC-type transporters confer multixenobiotic resistance and form an environment-tissue barrier in bivalve gills Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2008; 294(6): R1919 - R1929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Henrich, R. W. Robey, H. R. Bokesch, S. E. Bates, S. Shukla, S. V. Ambudkar, M. Dean, and J. B. McMahon New inhibitors of ABCG2 identified by high-throughput screening Mol. Cancer Ther., December 1, 2007; 6(12): 3271 - 3278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-P. Wu, S. Shukla, A. M. Calcagno, M. D. Hall, M. M. Gottesman, and S. V. Ambudkar Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter Mol. Cancer Ther., December 1, 2007; 6(12): 3287 - 3296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Shukla, C.-P. Wu, K. Nandigama, and S. V. Ambudkar The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance linked ATP binding cassette drug transporter ABCG2 Mol. Cancer Ther., December 1, 2007; 6(12): 3279 - 3286. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Balasubramanian, B. Mirnikjoo, and A. J. Schroit Regulated Externalization of Phosphatidylserine at the Cell Surface: IMPLICATIONS FOR APOPTOSIS J. Biol. Chem., June 22, 2007; 282(25): 18357 - 18364. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Petrovic, S. Teng, and M. Piquette-Miller REGULATION OF DRUG TRANSPORTERS: DURING INFECTION AND INFLAMMATION Mol. Interv., April 1, 2007; 7(2): 99 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Linton Structure and Function of ABC Transporters Physiology, April 1, 2007; 22(2): 122 - 130. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
